ABSTRACT

The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b):

5

$$R^5$$
 R^4
 $(CH_2)n$
 R^4
 $(CH_2)n^*$
 $(1a)$
 R^2
 R^3
 $(1b)$

enantiomers, diastereomers, salts and solvates thereof wherein R^1 , R^2 , R^3 , R^4 , R^5 , and R^7 are as defined herein. The invention further includes a method of CCR5-mediated disorders employing such compounds.